Delphine Déniel Lagadec^1,2,*, Laurence Guen^1,2, Fabienne Le Goc Le Sager¹, Sandrine Estivin^1,3, Christophe Perrin^1,4

Oncologie, Vol.23, No.1, pp. 39-46, 2021, DOI:10.32604/Oncologie.2021.015985

Abstract Since October 2020, the COVID-19 epidemic has affected the care of patients in the field of oncology/hematology in the public and private establishments. The “Unité de coordination en onco-geriatrie région Bretagne” (coordinating unit in onco-geriatrics of the Brittany region) has wished to have a survey with specialists in cancerology so as to make an inventory of the care given to cancer patients aged over 75 in the region. An inquest was made in the course of October 2020, following the first lock down, with 24 specialists. 67% of them feel they lack in clear orders/institutional prescriptions related with this epidemic.… More >

Yuan Liu^1,2,#, Yun Jia³, Bing Zhang², Anwen Liu^1,*

Oncologie, Vol.23, No.1, pp. 61-72, 2021, DOI:10.32604/Oncologie.2021.015906

Abstract Gastric cancer (GC) is the most common digestive system malignant tumor and second most common cause of cancer-related death. Even for the early gastric cancer, after radical operation, perioperative and postoperative chemotherapy the recurrence and metastasis are also high. 5-year overall survival of all GC patients is only 10–15%. Chemo-resistance still poses a major obstacle to successful treatment of GC. The aberrant expression of TUG1 (Taurine Upregulated Gene 1) was closely related to chemo-resistance and metastasis in many cancers. Here we over-expressed TUG1 in GC cell line SGC-7901 and MGC-803. We compared the migration ability and sensitivity of cisplatin (CDDP),… More >

Pierre-Guillaume Poureau^1,2,*, Jean-Philippe Metges²

Oncologie, Vol.23, No.1, pp. 47-59, 2021, DOI:10.32604/Oncologie.2021.15525

Abstract Immunotherapy for digestive cancers is booming and for the first time an immune checkpoint inhibitor has been granted marketing authorization for the treatment of digestive cancer. In order to better understand the mecanism of action of these treatments, their adverse events and the escape mecansim, it is necessary to know the fundamentals of cancer immunology. The innate and adaptive immune system allows the elimination of cancer cells by direct non-specific cytotoxicity (Natural Killer cells), by the development of an adaptive cell-mediated response (dendritic cells becoming antigen presenting cells, allowing the differentiation of lymphocytes naive in CD4 and CD8 T lymphocytes)… More >

Shivangi Goyal, Sreemoyee Chatterjee, Nidhi Gupta^*

Oncologie, Vol.23, No.1, pp. 89-104, 2021, DOI:10.32604/Oncologie.2021.015234

Abstract Background: Trigonella foenum-graecum Linn. has been extensively used for medicinal purposes. The current study deals with in vitro and in vivo correlation of free radical quenching activity and anticancer potential of seed extracts of Trigonella. Materials and methods: Antioxidant activity was evaluated against DPPH, NO and ABTS via in vitro radical scavenging assay. Cytotoxicity effect of Trigonella seed extract was studied in human embryonic kidney HEK 293 cell line by alamar blue assay. In vivo antioxidant activity in Swiss albino mice model was assessed by studying endogenous antioxidant enzymes such as GSH, GPx, SOD and LPO. Antitumor effect was observed… More >

Afiqah Halim¹, Wan Azani Mustafa^1,2,*, Wan Khairunizam Wan Ahmad¹, Hasliza A. Rahim², Hamzah Sakeran³

Oncologie, Vol.23, No.1, pp. 73-88, 2021, DOI:10.32604/Oncologie.2021.015154

Abstract Cervical cancer is a cell disease in the cervix that develops out of control in the female body. The cervix links the vagina (birth canal) with the upper section of the uterus, which can only be found in the female body. This is the second leading cause of death among women around the world. However, cervical cancer is currently one of the most preventable cancers if early detection is identified. The effect of unidentified cancer may increase the risk of death when the cell disease spreads to other parts of the female anatomy (metastasize). The Papanicolaou test is a cervical… More >

Xiaolin Wu, Lanping Diao, Guimin Zhao, Chen Huang, Yingzhen Yao, Zhe Gao, Lili Wu^*

Oncologie, Vol.23, No.1, pp. 141-148, 2021, DOI:10.32604/Oncologie.2021.014790

Abstract This study aimed to investigate the relationship and diagnostic potential between microsatellite instability (MSI) caused by a 9-bp GGGGGTAGA insertion/deletion in mitochondrial DNA (mtDNA) at position 8272 and clinical features in Chinese patients diagnosed with non-Hodgkin’s lymphoma. The 9-bp GGGGGTAGA insertion/deletion in the non-d-loop area of the mitochondrial DNA at the 8272 locus was detected by PCR in 139 non-Hodgkin’s lymphoma patient samples. GGGGGTAGA insertion/deletion was found in a total of 16 cases (11.5%), including nine T cell lymphoma and seven B cell lymphoma cases. The 5-year survival rate was 33.3% in patients with non-Hodgkin’s lymphoma and MSI, and was… More >

Erkan Arslan^1,*, Ismail Koyuncu²

Oncologie, Vol.23, No.1, pp. 105-117, 2021, DOI:10.32604/Oncologie.2021.014764

Abstract Prostate cancer is the second most common cancer in men. Prostate-specific antigen (PSA) levels, commonly used in the diagnosis of prostate cancer, are increased in both malign and benign conditions, such as prostate hyperplasia (BPH) and prostatitis. Thus, more specific markers are urgently needed to discriminate between prostate cancer and benign diseases of the prostate. The purpose of this study is to examine both the intracellular and extracellular free amino acid profiles of metastatic prostate cancer cells (PC-3), normal prostate cells (PNT-1A), and metabolic changes (e.g., pH). In this study, cancer and normal cells were incubated in the appropriate medium.… More >

Fei Han¹, Jianghong Qu², Fengyue Li¹, Dapeng Zhang³, Jiangming Qu⁴, Guanghua Li^5,*

Oncologie, Vol.23, No.1, pp. 131-140, 2021, DOI:10.32604/Oncologie.2021.014153

Abstract Aim: This study aims to explore the role of serum long non-coding RNA (lncRNA) colon cancer-associated transcript 2 (CCAT2) as a diagnostic marker for gastric cancer (GC). Methods: We recruited 76 patients with GC admitted to our hospital (the observation group, OG) and 83 healthy volunteers undergoing physical examinations during the same period (the control group, CG). CCAT2 expression was tested and its correlation with clinicopathological characteristics of GC was analyzed. We also explored the value of CCAT2 in assessing the treatment efficacy, predicting the fatality, and evaluating the prognosis of patients. Results: We detected higher CCAT2 levels in OG… More >

Xin Chang^1,2,#,*, Jin Wang^2,#, Caifang Ni¹

Oncologie, Vol.23, No.1, pp. 119-130, 2021, DOI:10.32604/oncologie.2021.014152

Abstract Objective: This research was designed to observe the value of miR-1271 and GPC3 in evaluating the prognosis of liver cancer (LC) patients after liver transarterial chemoembolization (TACE). Methods: A total of 80 patients diagnosed as LC in our hospital from January 2018 to April 2019 were included in the LC group (LCG), and then assigned into a survival group (SG) and a death group (DG) based on prognosis. Seventy healthy subjects undergoing physical examination simultaneously were included in the normal group (NG). miR-1271 and GPC3 in serum of two groups of subjects were tested via qRT-PCR. ROC curve was drawn.… More >

Lu Cao^1,*, Dianmei Yang², Bin Bai³

Oncologie, Vol.23, No.1, pp. 149-158, 2021, DOI:10.32604/oncologie.2021.014151

Abstract Objective: This study aimed to explore the miR-1247-mediated promotion of osteosarcoma (OS) cell proliferation by SOX9. Methods: We recruited 97 OS patients admitted to our hospital (the observation group, OG) and 82 healthy people undergoing physical examinations (the control group, CG) over the same period into this study. The expression of miR-1247 and SOX9 in human OS cells in vitro was tested to determine the effect of miR-1247 and SOX9 on OS and to analyze the relationship between miR-1247 and SOX9. Results: We detected lowly expressed miR-1247 and highly expressed SOX9 in the peripheral blood of OS patients (P <… More >